{
}
PureTech Health has appointed UBS as its UK Corporate Broker, a strategic decision aimed at enhancing its financial operations and market presence in the UK. This partnership is expected to bolster the company's industry standing and provide greater value to stakeholders through improved market engagement.As a clinical-stage biotherapeutics company, PureTech Health focuses on developing innovative medicines for serious diseases, boasting a pipeline of 29 therapeutics, three of which have received FDA approval. The company currently has a market cap of £362M and a year-to-date price performance of 0.67%.
[PureTech Health]
PureTech Health has appointed UBS as its UK Corporate Broker to enhance its market presence. This strategic move aims to improve corporate advisory and market-making services, potentially increasing visibility and relationships with institutional investors in the UK. PureTech, a clinical-stage biotherapeutics company, has developed a robust pipeline of 29 therapeutics, including three FDA-approved candidates.
Teva/Sanofi's Phase IIb data for their anti-TL1A agent in ulcerative colitis and Crohn’s disease has been described as potentially best in class, raising competitive stakes against Merck and Roche. Meanwhile, PureTech's deupirfenidone has outperformed Roche's Esbriet in a Phase IIb trial for idiopathic pulmonary fibrosis, positioning the company to finalize its Phase III program and explore financing options.
PureTech continues to focus on developing innovative medicines backed by human pharmacological evidence, aiming to bridge the value disconnect for shareholders. Despite market fluctuations, the firm believes that solid value propositions will attract investment, as demonstrated by the success of Karuna and Seaport. The systematic approach to addressing unmet medical needs remains central to their strategy, emphasizing that significant problems can often be solved with straightforward solutions.
Seaport Therapeutics has raised $225 million to advance its development of innovative brain drugs, focusing on longer-lasting psychiatric medications with fewer side effects. Founded by PureTech Health, the company is progressing its lead oral drug targeting major depressive disorder and exploring treatments for anxiety and neuropsychiatric disorders. The funding round, led by General Atlantic, reflects strong investor confidence in Seaport's experienced team and its promising research programs.
PureTech Health plc
Companies
| Symbol | PRTC |
| Name | PureTech Health plc |
| Currency | USD |
| Sector | Health Care |
| IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences |
| Industry | Biotechnology |
| Market | NASDAQ Global Select |
| Country | United States |
| State | MA |
| City | Boston |
| Zipcode | 2210 |
| Website | http://www.puretechhealth.com |
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
PureTech Health appoints UBS to enhance UK market presence and support
08:10 06.01.2025
PureTech Health appoints UBS as UK corporate broker to enhance market presence
08:00 06.01.2025
PureTech Health appoints UBS to strengthen UK corporate brokerage services
08:00 06.01.2025
Teva and PureTech report promising Phase IIb trial results in key therapies
23:56 17.12.2024
puretech focuses on proven therapies to bridge biotech value disconnect
17:40 21.10.2024
seaport therapeutics secures 225 million for brain drug development initiatives
Seaport Therapeutics
Sage Therapeutics, Inc.
PureTech Health plc
General Atlantic Fino A LLC
Karuna Therapeutics Inc.
Daphne Zohar
Steven Paul
Show more
16:05 21.10.2024
Trending
Subcategory
Industry Trends
Corporate News
Global Trade Developments
Government Economic Policies
Supply Chain Management
Startups & Entrepreneurship
Retail and Consumer Goods
Energy Sector Developments
Cryptocurrency & Blockchain Regulations
Emerging Startups
Funding Rounds & Investments
Industry Mergers & Acquisitions
Banking & Investment Regulations
Stock Market Updates
Anti-Money Laundering (AML) Regulations
Tax Policy & Corporate Taxation
CEO Changes
Foreign Exchange Rates
Financial Scams and Security
Finance Mergers & Acquisitions
Countries:
Companies:
Apple Inc.
Learning Resources Inc.
MGA Entertainment Inc.
State Street Global Advisors Luxembourg SICAV - SSGA EMU ESG Screened Equity Fund
European Union Bonds
SLB 4,6% 01JUN25
Equinor Ventures AS
Quanta Services, Inc.
Gold Circuit Electronics Ltd.
Unimicron Technology Corp.
Yatra Online, Inc.
Daiwa Institute OF Research Ltd.
Pegatron Corporation
KODEX India Tata Group
Wistron Corporation
Foxconn Technology Co., Ltd.
Volkswagen AG
XIAOMI-W
XPeng Inc.
Tesla, Inc.
Currencies:
United States Dollar
Chinese Yuan
Indian Rupee
United Arab Emirates Dirham
Japanese Yen
Vietnamese Đồng
New Taiwan Dollar
Euro
Australian Dollar
Thai Baht
Saudi Riyal
People: